Skip to main content

ASCIA Submissions 2024

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA submitted a response on 7 October 2024 to the Royal Australasian College of Physicians (RACP) call for feedback on the Development of the Clinical Immunology and Allergy Advanced Training Curriculum. This was an opportunity to review and provide professional insights, with the redesign enabling development of best practice education and assessment models. In compiling this feedback ASCIA sought input from the ASCIA Directors and Chairs of the Adult Practice, Anaphylaxis, Drug Allergy, Immunodeficiency and Paediatric Practice Committees. Emails from ASCIA were also sent to ASCIA Full and Associate Trainee members, in case they wished to provide feedback directly to the RACP.
    pdfASCIA letter RACP 07 OCT 2024192.75 KB
  • ASCIA lodged four confidential submissions on 9 July 2024 regarding PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis for consideration at the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting under "Other Matters (Change to existing listing)". The PBAC outcomes for the July 2024 meeting are on the PBS website: pbac-web-outcomes-07-2024.pdf (pbs.gov.au) and the entry for dupilumab is on page 28. Submissions were made to the PBAC, Sanofi, the Health Minister and the Assistant Health Minister.
    pdfASCIA letter PBAC DUPIXENT 2024-07-09110.13 KB

2024